Furthermore, we found the gene expression of PRKD3 and MET within Hippo relevant pathways were able to stratify tamoxifen-treated ERα + patients into better and worse groups of relapse-free survival (RFS), respectively (Fig. 4D, E), supporting a notion that PRKD3 and MET may be used as predictive biomarkers for response to endocrine therapy in ERα + breast cancer patients. This evidence concerns the gene MET and breast cancer.